| Literature DB >> 32130773 |
Markus V Heppt1,2, Ulrike Leiter3, Theresa Steeb1, Teresa Amaral3, Andrea Bauer4, Jürgen C Becker5, Eckhard Breitbart6, Helmut Breuninger3, Thomas Diepgen7, Thomas Dirschka8, Thomas Eigentler3, Michael Flaig1, Markus Follmann9, Klaus Fritz10, Rüdiger Greinert6, Ralf Gutzmer11, Uwe Hillen12, Stephan Ihrler13, Swen Malte John14, Oliver Kölbl15, Klaus Kraywinkel16, Christoph Löser17, Dorothée Nashan18, Seema Noor3, Monika Nothacker19, Christina Pfannenberg20, Carmen Salavastru10, Lutz Schmitz21, Eggert Stockfleth21, Rolf-Markus Szeimies22, Claas Ulrich23, Julia Welzel24, Kai Wermker25, Carola Berking1,2, Claus Garbe3.
Abstract
Actinic keratoses (AK) are common lesions in light-skinned individuals that can potentially progress to cutaneous squamous cell carcinoma (cSCC). Both conditions may be associated with significant morbidity and constitute a major disease burden, especially among the elderly. To establish an evidence-based framework for clinical decision making, the guideline "actinic keratosis and cutaneous squamous cell carcinoma" was developed using the highest level of methodology (S3) according to regulations issued by the Association of Scientific Medical Societies in Germany (AWMF). The guideline is aimed at dermatologists, general practitioners, ENT specialists, surgeons, oncologists, radiologists and radiation oncologists in hospitals and office-based settings as well as other medical specialties involved in the diagnosis and treatment of patients with AK and cSCC. The guideline is also aimed at affected patients, their relatives, policy makers and insurance funds. In the first part, we will address aspects relating to diagnosis, interventions for AK, care structures and quality-of-care indicators.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32130773 DOI: 10.1111/ddg.14048
Source DB: PubMed Journal: J Dtsch Dermatol Ges ISSN: 1610-0379 Impact factor: 5.584